Center of Excellence in Real-World Evidence

“Understanding what medications do to people, and what people do to medications.”
The Center seeks to improve the understanding of how medications work in real-world settings so that clinicians, patients, policy makers and health systems can make better decisions about healthcare.
Real-world evidence (RWE) is data collected from patients in their everyday lives, outside of clinical trials. RWE can be used to understand how medications work in real-world settings, including how well they are tolerated, how effective they are, and how they interact with other medications. The Center for Excellence in Real-world Evidence provides support for research and training, and is a leading resource for high-quality research on medication usage, risks, and effectiveness among large populations.
The Center leverages large datasets to generate knowledge on medications by using sophisticated analytic techniques to get the most accurate, precise, and timely estimates to improve public health. This evidence complements data and knowledge from randomized, controlled trials.
Carlos Alvarez, Pharm.D., MSc, MSCS
Center Director, Associate Professor, Pharmacy Practice
Focus of Research: Dr. Alvarez is primarily engaged in research focusing on pharmacoepidemiology, drug safety, and effectiveness using large administrative and clinical databases
Nadezhda German, Ph.D.
Associate Professor and Director of Medicinal Chemistry, Pharmaceutical Sciences
Focus of Research: Dr. German’s research focuses on early-stage and preclinical drug discovery, with an emphasis on developing anticancer and CNS agents.
Krystal Haase, Pharm.D.
Professor and SOP Amarillo Regional Dean, Pharmacy Practice
Focus of Research: Dr. Haase’s research explores the accessibility of pharmacists and their impact on patient outcomes, with a focus on optimizing clinical care and healthcare delivery.
Ronald G. Hall, Pharm.D., MSCS
Associate Professor, Pharmacy Practice
Focus of Research: Dr. Hall harnesses advanced analyses of national EHR data to evaluate antimicrobial utilization, effectiveness, and safety.
Ninh "Irene" La-Beck, Pharm.D.
Associate Professor, Immunotherapeutics and Biotechnology
Focus of Research: Dr La-Beck's research seeks to understand and exploit interactions between nanoparticles and the immune system to develop safer and more effective cancer treatments
Chris Selby, Pharm.D.
Associate Professor, Pharmacy Practice
Focus of Research: Dr. Selby’s research focuses on optimizing the safety and efficacy of anticancer agents.
Meredith Sigler, Pharm.D.
Assistant Professor, Pharmacy Practice
Aaron Perkins, MS
Chief Analyst
Christine Vu, MPH
Chief Analyst
Hui "Hanna" Yang, MS
Biostatistician
- Title: Treatment and resource utilization patterns in migraine patients within the Veterans Health Administration
- Investigators: Alvarez PI
- Funding Agency: Pfizer
- Description: This research characterizes the therapeutic approaches and healthcare resource utilization patterns of veterans being treated for migraines within the VA health system.
- Title: Prevalence and impact of the penicillin allergy label within the VHA
- Investigators: Arasaratnam PI
- Funding Agency: VA North Texas HCS
- Description: This research determines the frequency of documented penicillin allergies among the veteran population and assesses the associated consequences for antimicrobial stewardship efforts and adverse patient event.
- Title: Real-World Treatment Patterns And Outcomes Among Patients With Myelofibrosis In The Veterans Affairs Corporate Data Warehouse And Central Cancer Registry
- Investigators: Alvarez PI
- Funding Agency: Bristol Myers Squibb
- Description: This investigation characterizes the real-world therapeutic regimens and associated clinical outcomes for myelofibrosis patients by analyzing data from the Veterans Affairs Corporate Data Warehouse and Central Cancer Registry
- Title: A retrospective cohort study using Cerner Health Facts to evaluate the use ceftolozane/tazobactam in patients with bacteremia due to gram-negative pathogens
- Investigators: Hall PI
- Funding Agency: Merck
- Description: Utilizing the Cerner Health Facts database, this retrospective cohort study assesses the prescribing patterns and associated outcomes of ceftolozane/tazobactam for treating patients with bloodstream infections caused by gram-negative pathogens.
- Title: Long-term adherence to oral endocrine therapy among underserved breast cancer patients
- Investigators: Murphy PI
- Funding Agency: American Cancer Society
- Description: This research characterizes the rates and predictors of non-adherence to oral endocrine therapy over time within an underserved cohort of breast cancer survivors.
- Title: Association of diuretics with change in extracellular volume, natriuretic peptides, symptoms, and cardiovascular outcomes in CKD
- Investigators: Gregg PI
- Funding Agency: Veterans Affairs (IK2 CX002368-01A1)
- Description: This study investigates the association between diuretic therapy and subsequent changes in extracellular volume, natriuretic peptide levels, patient-reported symptoms, and cardiovascular outcomes among individuals with chronic kidney disease.
- Title: UT Southwestern Center for Translational Medicine
- Investigators: Toto PI
- Funding Agency: NIH/NCATS (UL1TR003163)
- Description: The UT Southwestern Clinical and Translational Science Award (CTSA) Program is a research hub designed to accelerate the transformation of scientific discoveries into improved health outcomes for the diverse communities of North Texas and beyond.
- Alvarez CA, Hall RG 2nd, Lin S, Perkins AR, Mortensen EM. Impact of PCV13 and PPSV23 Vaccination on Invasive Pneumococcal Disease in Adults with Treated Rheumatoid Arthritis: A Population-Based Study. Microorganisms. 2024 Oct 16;12(10):2073. doi: 10.3390/microorganisms12102073. PMID: 39458381; PMCID: PMC11510061.
- La-Beck NM, Lee YR, Patel J, Yang H, Stout M, Kologey A, Ruesewald A, Alvarez CA. Clinical Characteristics and Patterns of Immune Responses in COVID-19 Patients From a Rural Community Hospital. Cureus. 2024 Jun 3;16(6):e61600. doi: 10.7759/cureus.61600. PMID: 38962589; PMCID: PMC11221625.
- Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. JAMA Intern Med. 2021 Oct 4. doi: 10.1001/jamainternmed.2021.5714. Epub ahead of print. PMID: 34605849.
- Alvarez CA, Hall RG 2nd, Lin S, Perkins AR, Mortensen EM. Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population. Vaccine. Published online January 3, 2024. doi:10.1016/j.vaccine.2023.12.075
- Odeleye V, Masarweh O, Restrepo J, Alvarez CA, Mansi IA. Association of Strict Versus Lenient Cholesterol Lowering with Cardiac Outcomes, Diabetes Progression and Complications, and Mortality in Patients with Diabetes Treated with Statins: Is Less More?. Drug Saf. 2023 Oct 2;. doi: 10.1007/s40264-023-01347-8. [Epub ahead of print] PubMed PMID: 37782373.
- Afify H, Gonzalez-Morales U, Asmar A, Alvarez CA, Mansi IA. Association of Thiazide Diuretics With Diabetes Progression, Kidney Disease Progression, Cardiovascular Outcomes, and Death Among Patients With Diabetes Who Initiate Statins. Am J Cardiol. 2023 Sep 15;203:274-284. doi: 10.1016/j.amjcard.2023.07.057. Epub 2023 Jul 27. PubMed PMID: 37516035.
- Pharmacoepidemiolog
- Pharmacoeconomics
- Implementation Science
- Biostatistics
- Veteran Affairs Corporate Data Warehouse
- Oracle Health Data
- Optum Labs
- IBM MarketScan
- UT Southwestern Medical Center
- North Texas VA Healthcare System
- Parkland Health
- The University of California, Los Angeles
- Baylor College of Medicine
- University of Connecticut (UConn)
- University of Pennsylvania
- University of Texas at Austin
For Academic and Clinical Researchers:
- A Collaborative Ecosystem: Join a network of esteemed researchers and gain access to new funding opportunities and interdisciplinary projects.
- Rich Data Resources: Leverage our extensive real-world data assets to explore your research questions on a large scale.
- Methodological and Biostatistical Support: Our expert team can provide the support you need to design and execute high-impact studies.
- Training and Mentorship: We are committed to fostering the next generation of RWE researchers through comprehensive training programs and mentorship opportunities.
For Pharmaceutical and MedTech Industry Partners:
- Unparalleled Expertise: Our team consists of leading epidemiologists, data scientists, and clinicians with deep experience in RWE methodologies and regulatory requirements.
- Access to Rich Data: We have access to vast and diverse real-world datasets, enabling us to conduct large-scale studies that deliver meaningful and generalizable results.
- End-to-End Support: From study design and protocol development to data analysis and dissemination, we provide comprehensive support to ensure the success of your research projects.
- Credibility and Independence: As a trusted academic institution, our research is conducted with the highest standards of scientific rigor, lending credibility to product value proposition.
For Healthcare Systems and Payers:
- Comparative Effectiveness Research: We can help you compare the effectiveness of different treatments in your specific patient populations to identify the most clinically and cost-effective options.
- Population Health Management: Our research can inform your population health strategies by identifying unmet needs and opportunities for intervention.
- Quality Improvement Initiatives: We can partner with you to evaluate and optimize your clinical pathways and quality improvement programs.
Phone: 214.358.9031
Email: Carlos.Alvarez@ttuhsc.edu